7267 Study of the effect of GnRHa on BMI in girls with central precocious puberty

Disclosure: L. Lin: None. L. Ouyang: None. F. Yang: None. Background: In recent years, childhood obesity has garnered increasing attention. Although a correlation between obesity and central precocious puberty has been established, the underlying mechanisms remain incompletely understood. Gonadotropin-releasing hormone analogues are currently a common clinical intervention for treating CPP. Previous studies have predominantly focused on the enhancement of height following treatment. However, there is limited research on the impact of treatment on BMI, with some studies presenting conflicting results. Our study aims to assess the efficacy of GnRHa and investigate whether GnRHa treatment influences BMI. Methods: This study adopted an observational and retrospective design, enlisting a cohort of girls diagnosed with CPP. The study cohort was categorized into normal weight, overweight, and obese groups according to BMI values recorded at the initial diagnosis. Changes in clinical parameters, encompassing height, weight, BMI, bone age, and hematological markers, were systematically analyzed for the entire study population and subgroups at initial diagnosis, 12 months, and 24 months. Disparities in clinical parameters across various groups of girls were meticulously compared. Results: At the initial diagnosis, the prevalence of obesity among girls with CPP was noted to be 26.5%. After 1 and 2 years of treatment, this prevalence decreased to 18.8% and 15.4%, respectively. In the overall cohort of girls with CPP, the BMI-SDS at baseline, one-year treatment, and two-year treatment were 0.9 (0.2-2.1), 1.0 (0.3-1.6), and 0.8 (0.1-1.3), respectively (p=0.407). Upon categorizing the study population based on BMI and conducting intragroup comparisons, the BMI-SDS for the normal weight group at baseline, after one year of treatment, and after two years of treatment were 0.3±0.5, 0.4±0.6, and 0.3±0.6, respectively (p=0.576). The BMI-SDS for the overweight group at baseline, after one year of treatment, and after two years of treatment were 1.5±0.2, 1.4±0.5, and 1.2±0.2, respectively (p=0.046). The BMI-SDS for the obese group at baseline, after one year of treatment, and after two years of treatment were 2.9±0.9, 2.6±1.4, and 2.3±1.2, respectively (p=0.106). Conclusion: In our study cohort, there was a high detection rate of obesity among girls with CPP, and the use of GnRHa did not contribute to an increase in the incidence of overweight and obesity among CPP girls. Furthermore, GnRHa treatment did not result in an elevation of BMI-SDS in girls with CPP. The anthropometric measurements in various groups after treatment aligned with current research findings. Presentation: 6/1/2024